Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Eleanor Malone
Emerging Company Profile: Finland's Forendo Pharma hopes an imminent improvement in diagnostic possibilities will eventually help it commercialize a drug for endometriosis, which it believes could enable more effective treatment of a disease that afflicts large numbers of women.
Most of the big pharma companies will report their third-quarter results over the next three weeks. As usual, Johnson & Johnson and Roche will get out of the blocks early on. Scrip considers what to expect from the two front-runners, in the first of our regular financial results previews.
With three products now approved in Europe and/or the US for Duchenne Muscular Dystrophy, an FDA decision pending on PCT Therapeutics' ataluren and multiple companies exploring different approaches in preclinical and clinical studies, Scrip provides an overview of the development landscape and commercial results to date.
Significant shifts in innovation for atopic dermatitis are behind the decision to close down the current R&D center of Nestlé group prescription dermatology business Galderma. The move affects around 550 employees in Sophia Antipolis, France, with only a small proportion likely to be offered jobs in a planned new center of excellence.
Headline data from GlaxoSmithKline's IMPACT study comparing its new triple therapy Trelegy Ellipta with the company's dual therapies Breo/Relvar Ellipta and Anoro Ellipta support the product's ability to reduce exacerbations in more severe COPD. However, the benefit of IMPACT in expanding GSK's respiratory sales may be limited given pricing pressures and the make-up of GSK's current portfolio.
With the FDA approval of Trelegy Ellipta, GlaxoSmithKline will enjoy first-to-market status with a LABA/LAMA/ICS triple combination therapy to treat COPD in the US. However, it faces the challenge of convincing payers.